Do analysts rate MDWD or NBRV?

MediWound presently has a consensus price target of $34.00, indicating a potential upside of 139.10%. Given MediWound's stronger consensus rating and higher possible upside, equities research analysts clearly believe MediWound is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend NBRV or EQ?

Equillium has a consensus target price of $7.57, indicating a potential upside of 169.45%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Equillium 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78

Do analysts rate TLSA or NBRV?

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, TLSA or NBRV?

Tiziana Life Sciences has higher earnings, but lower revenue than Nabriva Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Nabriva Therapeutics $35.59M 0.00 -$57.19M -$19.20 N/A

Do analysts rate NBRV or TNYA?

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 461.96%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Tenaya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Do analysts prefer NBRV or ABOS?

Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 181.29%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Nabriva Therapeutics (NBRV) Competitors

Compare

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

Should you buy Nabriva Therapeutics stock or one of its competitors? MarketBeat compares Nabriva Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nabriva Therapeutics include MediWound (MDWD), Equillium (EQ), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.

How does Nabriva Therapeutics compare to MediWound?

MediWound (NASDAQ:MDWD) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Nabriva Therapeutics has a net margin of -148.11% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

MediWound has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

In the previous week, MediWound had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for MediWound and 0 mentions for Nabriva Therapeutics. MediWound's average media sentiment score of 1.89 beat Nabriva Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the media.

Company	Overall Sentiment
MediWound	Very Positive
Nabriva Therapeutics	Neutral

46.8% of MediWound shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MediWound has higher earnings, but lower revenue than Nabriva Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

MediWound presently has a consensus price target of $34.00, indicating a potential upside of 139.10%. Given MediWound's stronger consensus rating and higher possible upside, equities research analysts clearly believe MediWound is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

MediWound beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Equillium?

Nabriva Therapeutics (NASDAQ:NBRV) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Equillium has a consensus target price of $7.57, indicating a potential upside of 169.45%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Equillium has higher revenue and earnings than Nabriva Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Equillium	$41.10M	4.32	-$22.40M	-$0.32	N/A

Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Equillium has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Equillium has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Equillium's return on equity of -61.43% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Equillium	N/A	-61.43%	-53.72%

0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Equillium had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Equillium and 0 mentions for Nabriva Therapeutics. Equillium's average media sentiment score of 0.93 beat Nabriva Therapeutics' score of 0.00 indicating that Equillium is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
Equillium	Positive

Summary

Equillium beats Nabriva Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

0.3% of Nabriva Therapeutics shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tiziana Life Sciences has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Tiziana Life Sciences' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

In the previous week, Tiziana Life Sciences had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 0 mentions for Nabriva Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.87 beat Nabriva Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Nabriva Therapeutics	Neutral

Tiziana Life Sciences has higher earnings, but lower revenue than Nabriva Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Given Nabriva Therapeutics' higher probable upside, analysts plainly believe Nabriva Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Tiziana Life Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

Summary

Tiziana Life Sciences beats Nabriva Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Nabriva Therapeutics (NASDAQ:NBRV) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Nabriva Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Tenaya Therapeutics	$225K	686.49	-$90.60M	-$0.47	N/A

Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 461.96%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tenaya Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Tenaya Therapeutics' return on equity of -80.56% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, meaning that its share price is 182% more volatile than the broader market.

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Tenaya Therapeutics and 0 mentions for Nabriva Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.87 beat Nabriva Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
Tenaya Therapeutics	Very Positive

Summary

Tenaya Therapeutics beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Nabriva Therapeutics (NASDAQ:NBRV) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Nabriva Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

0.3% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.6% of Nabriva Therapeutics shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 181.29%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Acumen Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Acumen Pharmaceuticals' return on equity of -123.07% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 0 mentions for Nabriva Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 0.59 beat Nabriva Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
Acumen Pharmaceuticals	Positive

Summary

Acumen Pharmaceuticals beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Nabriva Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBRV vs. The Competition

Export

Metric	Nabriva Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$45.46M	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.45	24.00	24.42
Price / Sales	N/A	120.49	514.65	112.54
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	7.85	10.69	6.82
Net Income	-$57.19M	-$4.88M	$3.57B	$337.56M

Nabriva Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
MDWD MediWound	3.4827 of 5 stars	$13.74 -0.1%	$34.00 +147.4%	-30.4%	$176.85M	$16.96M	N/A	80
EQ Equillium	2.9703 of 5 stars	$3.11 +11.5%	$7.57 +143.5%	+709.8%	$176.40M	$41.10M	N/A	40	Analyst Upgrade High Trading Volume
TLSA Tiziana Life Sciences	1.0164 of 5 stars	$1.18 -13.2%	N/A	-29.0%	$173.07M	N/A	N/A	8	Positive News Upcoming Earnings Gap Up High Trading Volume
TNYA Tenaya Therapeutics	2.5488 of 5 stars	$0.79 -0.5%	$4.00 +409.0%	+20.3%	$171.43M	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBRV) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nabriva Therapeutics (NBRV) Competitors

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does Nabriva Therapeutics compare to MediWound?

Summary

How does Nabriva Therapeutics compare to Equillium?

Summary

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Summary

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Summary

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV vs. The Competition

Nabriva Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nabriva Therapeutics (NBRV) Competitors

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does Nabriva Therapeutics compare to MediWound?

Is MDWD or NBRV more profitable?

Which has more risk & volatility, MDWD or NBRV?

Does the media favor MDWD or NBRV?

Do insiders and institutionals have more ownership in MDWD or NBRV?

Which has higher valuation and earnings, MDWD or NBRV?

Do analysts rate MDWD or NBRV?

Summary

How does Nabriva Therapeutics compare to Equillium?

Do analysts recommend NBRV or EQ?

Which has preferable earnings & valuation, NBRV or EQ?

Which has more risk & volatility, NBRV or EQ?

Is NBRV or EQ more profitable?

Do institutionals & insiders have more ownership in NBRV or EQ?

Does the media prefer NBRV or EQ?

Summary

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Do insiders & institutionals believe in TLSA or NBRV?

Is TLSA or NBRV more profitable?

Does the media prefer TLSA or NBRV?

Which has higher valuation and earnings, TLSA or NBRV?

Do analysts rate TLSA or NBRV?

Which has more volatility and risk, TLSA or NBRV?

Summary

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Which has higher earnings & valuation, NBRV or TNYA?

Do analysts rate NBRV or TNYA?

Do insiders and institutionals hold more shares of NBRV or TNYA?

Is NBRV or TNYA more profitable?

Which has more volatility & risk, NBRV or TNYA?

Does the media refer more to NBRV or TNYA?

Summary

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Which has more risk and volatility, NBRV or ABOS?

Which has stronger earnings and valuation, NBRV or ABOS?

Do insiders and institutionals believe in NBRV or ABOS?

Do analysts prefer NBRV or ABOS?

Is NBRV or ABOS more profitable?

Does the media refer more to NBRV or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV vs. The Competition

Nabriva Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools